View All News

Channelchek-in

<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>Key Points: - Small-cap defense companies operate in specialized sectors with higher agility and acquisition potential compared to mega-cap contractors - Cybersecurity, drone systems, and advanced materials offer the strongest growth opportunities in current geopolitical climate - Market volatility creates entry opportunities before institutional recognition drives valuations higher</td></tr></tbody></table></figure>



While major defense contractors like Lockheed Martin and Northrop Grumman capture headlines during geopolitical tensions, astute small-cap investors should turn their attention to the lesser-known defense players positioned to benefit from increased military spending and technological innovation. Small-cap defense companies often operate in specialized niches that make them indispensable to larger prime contractors and government agencies, and unlike their mega-cap counterparts, these firms can pivot quickly to emerging threats and technologies, making them attractive acquisition targets or compelling long-term growth stories.



The current geopolitical climate, highlighted by recent Middle East tensions and ongoing global conflicts, has created a sustained tailwind for defense spending. President Trump's pledge of a $1 trillion defense budget, while potentially falling short in fiscal 2026, signals a multi-year commitment to military modernization that extends far beyond traditional weapons systems. This environment particularly benefits small-cap companies specializing in cybersecurity and electronic warfare, where firms focusing on cyber defense, electronic countermeasures, and signal intelligence are experiencing unprecedented demand. These companies often possess proprietary technologies that are difficult to replicate and command premium margins, creating substantial competitive advantages.



The drone revolution presents another compelling opportunity, extending beyond consumer applications into military reconnaissance, logistics, and combat operations. Small-cap manufacturers of specialized UAV components, software, and support systems are capturing market share from traditional aerospace giants, while companies developing next-generation materials for armor, stealth applications, and extreme environment operations often fly under the radar while generating substantial returns for early investors.



When evaluating small-cap defense opportunities, successful investors focus on companies with government contract diversification across multiple agencies and international allies to reduce single-customer risk. The most attractive investments typically feature proprietary technology through patents and specialized expertise that create competitive moats justifying premium valuations. Experienced management teams with deep defense industry connections and security clearances consistently accelerate contract wins, while financial discipline demonstrated through strong balance sheets and consistent cash flow generation proves crucial despite the lumpy nature of contract timing.



Small-cap defense investing requires careful risk assessment, as government budget cycles, security clearance requirements, and regulatory compliance create unique challenges. However, companies that successfully navigate these hurdles often enjoy sustained competitive advantages and multi-year revenue visibility that reward patient investors. The current environment of elevated geopolitical tensions, combined with technological disruption in warfare, creates an ideal backdrop for small-cap defense investments. While large-cap names grab immediate attention during crisis periods, the real long-term value creation often occurs in the innovative small companies that power the next generation of military capabilities. Smart investors should use market volatility as an opportunity to build positions in quality small-cap defense names before institutional recognition drives valuations higher.

Key Points: &#8211; Small-cap defense companies operate in specialized sectors with higher agility and acquisition potential compared to mega-cap contractors&#8211; Cybersecurity, drone systems, and advanced materials offer the strongest growth opportunities in current geopolitical climate&#8211; Market volatility creates entry opportunities before institutional recognition drives valuations higher



While major defense contractors like Lockheed Martin and Northrop Grumman capture headlines during geopolitical tensions, astute small-cap investors should turn their attention to the lesser-known defense players positioned to benefit from increased military spending and technological innovation. Small-cap defense companies often operate in specialized niches that make them indispensable to larger prime contractors and government agencies, and unlike their mega-cap counterparts, these firms can pivot quickly to emerging threats and technologies, making them attractive acquisition targets or compelling long-term growth stories.



The current geopolitical climate, highlighted by recent Middle East tensions and ongoing global conflicts, has created a sustained tailwind for defense spending. President Trump&#8217;s pledge of a $1 trillion defense budget, while potentially falling short in fiscal 2026, signals a multi-year commitment to military modernization that extends far beyond traditional weapons systems. This environment particularly benefits small-cap companies specializing in cybersecurity and electronic warfare, where firms focusing on cyber defense, electronic countermeasures, and signal intelligence are experiencing unprecedented demand. These companies often possess proprietary technologies that are difficult to replicate and command premium margins, creating substantial competitive advantages.



The drone revolution presents another compelling opportunity, extending beyond consumer applications into military reconnaissance, logistics, and combat operations. Small-cap manufacturers of specialized UAV components, software, and support systems are capturing market share from traditional aerospace giants, while companies developing next-generation materials for armor, stealth applications, and extreme environment operations often fly under the radar while generating substantial returns for early investors.



When evaluating small-cap defense opportunities, successful investors focus on companies with government contract diversification across multiple agencies and international allies to reduce single-customer risk. The most attractive investments typically feature proprietary technology through patents and specialized expertise that create competitive moats justifying premium valuations. Experienced management teams with deep defense industry connections and security clearances consistently accelerate contract wins, while financial discipline demonstrated through strong balance sheets and consistent cash flow generation proves crucial despite the lumpy nature of contract timing.



Small-cap defense investing requires careful risk assessment, as government budget cycles, security clearance requirements, and regulatory compliance create unique challenges. However, companies that successfully navigate these hurdles often enjoy sustained competitive advantages and multi-year revenue visibility that reward patient investors. The current environment of elevated geopolitical tensions, combined with technological disruption in warfare, creates an ideal backdrop for small-cap defense investments. While large-cap names grab immediate attention during crisis periods, the real long-term value creation often occurs in the innovative small companies that power the next generation of military capabilities. Smart investors should use market volatility as an opportunity to build positions in quality small-cap defense names before institutional recognition drives valuations higher.

Small-Cap Defense Stocks: Hidden Gems in Times of Global Uncertainty

Defense

Geopolitical Tensions

Global Conflict

Middle East

Noble Capital Markets Research Morning Call

Stripe's acquisition of crypto wallet provider Privy represents far more than a simple technology purchase—it's a calculated move to position the payments giant at the forefront of the digital currency revolution. This strategic acquisition, coming on the heels of Stripe's massive $1.1 billion purchase of Bridge earlier this year, demonstrates the company's commitment to building a comprehensive cryptocurrency infrastructure that could fundamentally reshape how businesses and consumers interact with digital assets.



Privy's impressive scale provides immediate validation of the crypto wallet market's maturity. With over 75 million accounts across more than 1,000 developer teams facilitating billions in transactions, the New York-based startup has proven that cryptocurrency wallets can achieve mainstream adoption when properly executed. Founded in 2021 by Henri Stern and Asta Li, Privy solved a critical problem in the crypto ecosystem by creating developer-friendly APIs that eliminate the technical barriers traditionally associated with wallet creation and blockchain integration.



The timing of this acquisition is particularly significant given the broader cryptocurrency market's evolution toward practical utility rather than speculative trading. Privy's technology spans multiple high-growth sectors including decentralized finance, gaming, artificial intelligence agents, and consumer applications, indicating that crypto infrastructure is becoming integral to diverse business models rather than remaining confined to niche financial applications.



Stripe's strategic vision becomes clearer when considering how Privy's capabilities complement the company's existing strengths. The payments processor has built its reputation on simplifying complex financial operations for merchants, and cryptocurrency transactions represent the next logical frontier. By integrating Privy's wallet technology with Bridge's stablecoin infrastructure and Stripe's global payment network, the company is creating a unified platform that could make cryptocurrency transactions as seamless as traditional card payments.



The acquisition's structure reveals Stripe's confidence in Privy's independent value proposition. By allowing Privy to continue operating as an independent product, Stripe acknowledges that the crypto wallet market requires specialized expertise and dedicated focus. This approach mirrors successful technology acquisitions where the parent company provides resources and distribution while preserving the acquired company's innovative culture and technical capabilities.



Patrick Collison's statement about enabling "Internet-native financial services" hints at Stripe's larger ambition to challenge traditional banking infrastructure. The combination of wallet technology, stablecoin capabilities, and global payment processing creates a powerful alternative to conventional financial systems, particularly for international transactions where traditional banking remains slow and expensive.



The undisclosed acquisition price, while notable, is less important than the strategic implications. Privy's $40 million in raised capital from prominent investors including Ribbit Capital and Coinbase Ventures suggests a valuation multiple that reflects both current performance and future potential. For Stripe, which processes hundreds of billions in annual payment volume, the cost of this acquisition is minimal compared to the potential revenue from expanding into cryptocurrency infrastructure.



This acquisition positions Stripe to capture value from the inevitable growth in cryptocurrency adoption while maintaining its core business focus. As regulatory clarity improves and institutional adoption accelerates, companies with comprehensive crypto infrastructure will possess significant competitive advantages in the evolving digital economy.

Stripe&#8217;s acquisition of crypto wallet provider Privy represents far more than a simple technology purchase—it&#8217;s a calculated move to position the payments giant at the forefront of the digital currency revolution. This strategic acquisition, coming on the heels of Stripe&#8217;s massive $1.1 billion purchase of Bridge earlier this year, demonstrates the company&#8217;s commitment to building a comprehensive cryptocurrency infrastructure that could fundamentally reshape how businesses and consumers interact with digital assets.



Privy&#8217;s impressive scale provides immediate validation of the crypto wallet market&#8217;s maturity. With over 75 million accounts across more than 1,000 developer teams facilitating billions in transactions, the New York-based startup has proven that cryptocurrency wallets can achieve mainstream adoption when properly executed. Founded in 2021 by Henri Stern and Asta Li, Privy solved a critical problem in the crypto ecosystem by creating developer-friendly APIs that eliminate the technical barriers traditionally associated with wallet creation and blockchain integration.



The timing of this acquisition is particularly significant given the broader cryptocurrency market&#8217;s evolution toward practical utility rather than speculative trading. Privy&#8217;s technology spans multiple high-growth sectors including decentralized finance, gaming, artificial intelligence agents, and consumer applications, indicating that crypto infrastructure is becoming integral to diverse business models rather than remaining confined to niche financial applications.



Stripe&#8217;s strategic vision becomes clearer when considering how Privy&#8217;s capabilities complement the company&#8217;s existing strengths. The payments processor has built its reputation on simplifying complex financial operations for merchants, and cryptocurrency transactions represent the next logical frontier. By integrating Privy&#8217;s wallet technology with Bridge&#8217;s stablecoin infrastructure and Stripe&#8217;s global payment network, the company is creating a unified platform that could make cryptocurrency transactions as seamless as traditional card payments.



The acquisition&#8217;s structure reveals Stripe&#8217;s confidence in Privy&#8217;s independent value proposition. By allowing Privy to continue operating as an independent product, Stripe acknowledges that the crypto wallet market requires specialized expertise and dedicated focus. This approach mirrors successful technology acquisitions where the parent company provides resources and distribution while preserving the acquired company&#8217;s innovative culture and technical capabilities.



Patrick Collison&#8217;s statement about enabling &#8220;Internet-native financial services&#8221; hints at Stripe&#8217;s larger ambition to challenge traditional banking infrastructure. The combination of wallet technology, stablecoin capabilities, and global payment processing creates a powerful alternative to conventional financial systems, particularly for international transactions where traditional banking remains slow and expensive.



The undisclosed acquisition price, while notable, is less important than the strategic implications. Privy&#8217;s $40 million in raised capital from prominent investors including Ribbit Capital and Coinbase Ventures suggests a valuation multiple that reflects both current performance and future potential. For Stripe, which processes hundreds of billions in annual payment volume, the cost of this acquisition is minimal compared to the potential revenue from expanding into cryptocurrency infrastructure.



This acquisition positions Stripe to capture value from the inevitable growth in cryptocurrency adoption while maintaining its core business focus. As regulatory clarity improves and institutional adoption accelerates, companies with comprehensive crypto infrastructure will possess significant competitive advantages in the evolving digital economy.

Stripe's Crypto Wallet Acquisition: A Strategic Play for Digital Payment Dominance

Crypto

Digital Currency

Privy

Stripe

In a major step forward for the future of mRNA-based medicine, BioNTech SE has announced it will acquire fellow German biotech firm CureVac N.V. in an all-stock deal valued at approximately $1.25 billion. The transaction is set to bolster BioNTech’s capabilities in cancer immunotherapy and mRNA research, positioning the company for deeper innovation and broader commercialization in oncology.



Under the terms of the agreement, CureVac shareholders will receive approximately $5.46 in BioNTech American Depositary Shares (ADSs) for each CureVac share—representing a 55% premium over CureVac’s three-month average trading price. The exchange ratio will be adjusted depending on the 10-day average trading price of BioNTech stock leading up to the deal’s closure. Upon completion, CureVac shareholders are expected to own between 4% and 6% of BioNTech’s outstanding shares.



Both companies are pioneers in mRNA-based technologies, with BioNTech gaining international prominence for its COVID-19 vaccine co-developed with Pfizer. CureVac has long focused on developing mRNA therapeutics for cancer and infectious diseases. The deal unites two complementary platforms, merging BioNTech’s commercial success and oncology pipeline with CureVac’s expertise in mRNA design and lipid nanoparticle (LNP) delivery systems.



“This transaction is another building block in BioNTech’s oncology strategy and an investment in the future of cancer medicine,” said Prof. Ugur Sahin, CEO and Co-Founder of BioNTech. “By combining our strengths, we aim to accelerate the development of innovative and transformative cancer treatments that could become new standards of care.”



CureVac CEO Dr. Alexander Zehnder echoed Sahin’s sentiment, describing the acquisition as a shared mission rather than just a financial deal. “For more than 20 years, both companies have worked toward unlocking the potential of mRNA. This union represents a powerful convergence of technologies, cultures, and visions to push the boundaries of what’s possible in medicine,” Zehnder said.



The acquisition will integrate CureVac’s advanced R&amp;D and manufacturing site in Tübingen into BioNTech’s broader operations. CureVac will become a wholly owned subsidiary of BioNTech, and a full corporate reorganization will follow the completion of the exchange offer, expected later this year.



The deal already has substantial shareholder backing. CureVac’s largest investor, dievini Hopp BioTech, and its affiliates—which collectively hold over 36% of CureVac shares—have agreed to support the transaction. Including other key stakeholders and the German government’s investment arm, BioNTech expects support from shareholders holding more than 50% of CureVac’s shares, positioning the company well to meet the 80% acceptance threshold required to finalize the transaction.



The boards of both companies have unanimously approved the deal, which now awaits regulatory approval and final shareholder votes. Legal and financial advisors for the deal include Covington &amp; Burling LLP and PJT Partners for BioNTech, and Goldman Sachs and Skadden for CureVac.



This acquisition cements BioNTech’s strategy to lead the next generation of cancer therapies, leveraging the full power of mRNA science in the fight against some of the world’s most challenging diseases.



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><a href="https://www.channelchek.com/analysts/robert-leboyer">Take a moment to take a look at other emerging growth biotech companies by taking a look at Noble Capital Markets Research Analyst Robert Leboyer's coverage list. </a></td></tr></tbody></table></figure>

In a major step forward for the future of mRNA-based medicine, BioNTech SE has announced it will acquire fellow German biotech firm CureVac N.V. in an all-stock deal valued at approximately $1.25 billion. The transaction is set to bolster BioNTech’s capabilities in cancer immunotherapy and mRNA research, positioning the company for deeper innovation and broader commercialization in oncology.



Under the terms of the agreement, CureVac shareholders will receive approximately $5.46 in BioNTech American Depositary Shares (ADSs) for each CureVac share—representing a 55% premium over CureVac’s three-month average trading price. The exchange ratio will be adjusted depending on the 10-day average trading price of BioNTech stock leading up to the deal’s closure. Upon completion, CureVac shareholders are expected to own between 4% and 6% of BioNTech’s outstanding shares.



Both companies are pioneers in mRNA-based technologies, with BioNTech gaining international prominence for its COVID-19 vaccine co-developed with Pfizer. CureVac has long focused on developing mRNA therapeutics for cancer and infectious diseases. The deal unites two complementary platforms, merging BioNTech’s commercial success and oncology pipeline with CureVac’s expertise in mRNA design and lipid nanoparticle (LNP) delivery systems.



“This transaction is another building block in BioNTech’s oncology strategy and an investment in the future of cancer medicine,” said Prof. Ugur Sahin, CEO and Co-Founder of BioNTech. “By combining our strengths, we aim to accelerate the development of innovative and transformative cancer treatments that could become new standards of care.”



CureVac CEO Dr. Alexander Zehnder echoed Sahin’s sentiment, describing the acquisition as a shared mission rather than just a financial deal. “For more than 20 years, both companies have worked toward unlocking the potential of mRNA. This union represents a powerful convergence of technologies, cultures, and visions to push the boundaries of what’s possible in medicine,” Zehnder said.



The acquisition will integrate CureVac’s advanced R&amp;D and manufacturing site in Tübingen into BioNTech’s broader operations. CureVac will become a wholly owned subsidiary of BioNTech, and a full corporate reorganization will follow the completion of the exchange offer, expected later this year.



The deal already has substantial shareholder backing. CureVac’s largest investor, dievini Hopp BioTech, and its affiliates—which collectively hold over 36% of CureVac shares—have agreed to support the transaction. Including other key stakeholders and the German government’s investment arm, BioNTech expects support from shareholders holding more than 50% of CureVac’s shares, positioning the company well to meet the 80% acceptance threshold required to finalize the transaction.



The boards of both companies have unanimously approved the deal, which now awaits regulatory approval and final shareholder votes. Legal and financial advisors for the deal include Covington &amp; Burling LLP and PJT Partners for BioNTech, and Goldman Sachs and Skadden for CureVac.



This acquisition cements BioNTech’s strategy to lead the next generation of cancer therapies, leveraging the full power of mRNA science in the fight against some of the world’s most challenging diseases.



Take a moment to take a look at other emerging growth biotech companies by taking a look at Noble Capital Markets Research Analyst Robert Leboyer&#8217;s coverage list.

BioNTech to Acquire CureVac in Strategic All-Stock Deal to Accelerate Cancer Immunotherapy Innovation

<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>Key Points: - Air India Boeing 787-8 crashes after takeoff, killing all 242 passengers and crew. - Boeing shares drop over 4% as safety concerns resurface following the incident. - Supplier stocks also fall amid fears of regulatory delays and scrutiny.</td></tr></tbody></table></figure>



Boeing’s stock took a sharp hit Thursday after a devastating crash involving an Air India Boeing 787-8 Dreamliner claimed the lives of over 200 people. The aircraft went down shortly after takeoff from Ahmedabad, India, en route to London’s Gatwick Airport, and is believed to have left no survivors among the 242 passengers and crew on board.



The Boeing 787-8 involved in the crash was delivered to Air India in 2014. While investigations into the cause of the incident are still underway, city officials confirmed that more than 200 bodies have already been recovered from the wreckage.



Shares of Boeing (NYSE: BA) dropped more than 4% by midday Thursday, trading around $204.88 — a sharp reversal for the aerospace giant, which had gained nearly 18% year-to-date thanks to a series of high-profile aircraft orders and what had been seen as a successful turnaround strategy under new CEO Kelly Ortberg.



In a brief statement, Boeing acknowledged the tragedy: “We are in contact with Air India regarding Flight 171 and stand ready to support them. Our thoughts are with the passengers, crew, first responders and all affected.” The company has yet to release any technical details or assessments regarding the crash.



This marks the first fatal incident involving the Boeing 787 Dreamliner since its introduction in 2011, according to Boeing’s aircraft safety records. The Dreamliner line has been considered one of Boeing’s flagship wide-body jets and was widely touted for its fuel efficiency, lightweight composite materials, and advanced onboard systems.



The crash adds to the list of major aviation tragedies tied to Boeing aircraft in recent years. The company is still recovering from the fallout of two deadly crashes involving its 737 Max 8 jets in 2018 and 2019. Those incidents, caused by software flaws, led to a 20-month worldwide grounding of the 737 Max and triggered numerous lawsuits, regulatory reforms, and a complete overhaul of Boeing’s safety and development processes.



Earlier this year, Boeing faced another crisis after a door panel on an Alaska Airlines 737 Max blew off mid-flight. That incident renewed safety concerns and prompted the resignation of former CEO Dave Calhoun, paving the way for Ortberg’s leadership. The company has since focused on rebuilding its reputation, tightening manufacturing oversight, and securing new contracts.



Thursday’s crash threatens to undo much of that progress. Analysts at Edward Jones warned that heightened regulatory scrutiny could delay future aircraft deliveries, potentially reducing Boeing’s cash flow. However, they noted that the company still retains a strong order backlog.



“While a delay in deliveries is possible, Boeing maintains a strong order book, and we think significant cancellations are unlikely given the lengthy wait times at Boeing’s primary competitor,” wrote Jeff Windau, senior industrials analyst at Edward Jones.



The tragedy also rippled through the broader aerospace sector. GE Aerospace, which manufactures engines for the 787, saw its shares fall more than 2%, while Spirit AeroSystems, a major supplier of fuselage components for Boeing aircraft, declined nearly 3%.



Investigators are expected to examine black box data, flight maintenance records, and crew communications to determine the cause of the crash. Both Boeing and global aviation authorities are closely watching developments as the company once again faces difficult questions about safety and accountability.

Key Points:&#8211; Air India Boeing 787-8 crashes after takeoff, killing all 242 passengers and crew.&#8211; Boeing shares drop over 4% as safety concerns resurface following the incident.&#8211; Supplier stocks also fall amid fears of regulatory delays and scrutiny.



Boeing’s stock took a sharp hit Thursday after a devastating crash involving an Air India Boeing 787-8 Dreamliner claimed the lives of over 200 people. The aircraft went down shortly after takeoff from Ahmedabad, India, en route to London’s Gatwick Airport, and is believed to have left no survivors among the 242 passengers and crew on board.



The Boeing 787-8 involved in the crash was delivered to Air India in 2014. While investigations into the cause of the incident are still underway, city officials confirmed that more than 200 bodies have already been recovered from the wreckage.



Shares of Boeing (NYSE: BA) dropped more than 4% by midday Thursday, trading around $204.88 — a sharp reversal for the aerospace giant, which had gained nearly 18% year-to-date thanks to a series of high-profile aircraft orders and what had been seen as a successful turnaround strategy under new CEO Kelly Ortberg.



In a brief statement, Boeing acknowledged the tragedy: “We are in contact with Air India regarding Flight 171 and stand ready to support them. Our thoughts are with the passengers, crew, first responders and all affected.” The company has yet to release any technical details or assessments regarding the crash.



This marks the first fatal incident involving the Boeing 787 Dreamliner since its introduction in 2011, according to Boeing’s aircraft safety records. The Dreamliner line has been considered one of Boeing’s flagship wide-body jets and was widely touted for its fuel efficiency, lightweight composite materials, and advanced onboard systems.



The crash adds to the list of major aviation tragedies tied to Boeing aircraft in recent years. The company is still recovering from the fallout of two deadly crashes involving its 737 Max 8 jets in 2018 and 2019. Those incidents, caused by software flaws, led to a 20-month worldwide grounding of the 737 Max and triggered numerous lawsuits, regulatory reforms, and a complete overhaul of Boeing’s safety and development processes.



Earlier this year, Boeing faced another crisis after a door panel on an Alaska Airlines 737 Max blew off mid-flight. That incident renewed safety concerns and prompted the resignation of former CEO Dave Calhoun, paving the way for Ortberg’s leadership. The company has since focused on rebuilding its reputation, tightening manufacturing oversight, and securing new contracts.



Thursday’s crash threatens to undo much of that progress. Analysts at Edward Jones warned that heightened regulatory scrutiny could delay future aircraft deliveries, potentially reducing Boeing’s cash flow. However, they noted that the company still retains a strong order backlog.



“While a delay in deliveries is possible, Boeing maintains a strong order book, and we think significant cancellations are unlikely given the lengthy wait times at Boeing’s primary competitor,” wrote Jeff Windau, senior industrials analyst at Edward Jones.



The tragedy also rippled through the broader aerospace sector. GE Aerospace, which manufactures engines for the 787, saw its shares fall more than 2%, while Spirit AeroSystems, a major supplier of fuselage components for Boeing aircraft, declined nearly 3%.



Investigators are expected to examine black box data, flight maintenance records, and crew communications to determine the cause of the crash. Both Boeing and global aviation authorities are closely watching developments as the company once again faces difficult questions about safety and accountability.

Boeing Shares Plunge After Fatal Air India Dreamliner Crash

Air India

Airplanes

Boeing

Plane Crash

Travel

<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>Key Points: - Oil prices jumped over 4% after reports of a partial U.S. embassy evacuation in Iraq raised geopolitical concerns. - Additional support came from President Trump's doubts over a nuclear deal with Iran, potentially limiting future oil supply. - A breakthrough in U.S.-China trade talks also boosted sentiment, helping crude extend its recent rally.</td></tr></tbody></table></figure>



Crude oil prices soared on Wednesday, climbing more than 4% amid escalating geopolitical tensions and renewed concerns over global supply disruptions. The sharp move followed reports that the U.S. embassy in Baghdad is preparing for a partial evacuation due to rising security threats.



West Texas Intermediate (WTI) crude futures closed at $68.15 per barrel, up 4.5%, while Brent crude, the global benchmark, settled at $69.77, a gain of 4%. The rally reflects growing unease in energy markets over the stability of the Middle East, a region critical to global oil production and transportation.



The price spike was triggered by a Reuters report indicating that U.S. and Iraqi officials are coordinating plans for an “ordered departure” of embassy personnel in Iraq. The development comes amid mounting threats in the region, raising fears that oil infrastructure or transportation routes could be impacted if tensions escalate further.



In addition to the embassy-related concerns, oil prices were also supported by comments from President Donald Trump, who expressed skepticism over the prospects of reaching a new nuclear agreement with Iran — a major oil-producing nation. Speaking during a podcast, Trump said his confidence in a deal had “diminished,” casting doubt on the potential return of sanctioned Iranian barrels to the market.



Oil prices found further support from signs of easing trade tensions between the U.S. and China. Following high-level discussions in London, both nations reportedly agreed to a framework aimed at reducing tariffs and improving trade flows. President Trump hinted that a formal agreement could be imminent, pending final approval from Chinese President Xi Jinping.



The latest surge adds to a month-long recovery in oil prices, which have rebounded from a sharp sell-off in April driven by global economic concerns and softer demand projections. Despite the rebound, both WTI and Brent remain down year-to-date, reflecting the broader market’s caution around demand durability and geopolitical risk.



Analysts are closely watching developments in the Middle East and diplomatic signals from Washington and Beijing, noting that any further escalation or policy shifts could significantly impact global supply dynamics in the weeks ahead

Key Points: &#8211; Oil prices jumped over 4% after reports of a partial U.S. embassy evacuation in Iraq raised geopolitical concerns.&#8211; Additional support came from President Trump&#8217;s doubts over a nuclear deal with Iran, potentially limiting future oil supply.&#8211; A breakthrough in U.S.-China trade talks also boosted sentiment, helping crude extend its recent rally.



Crude oil prices soared on Wednesday, climbing more than 4% amid escalating geopolitical tensions and renewed concerns over global supply disruptions. The sharp move followed reports that the U.S. embassy in Baghdad is preparing for a partial evacuation due to rising security threats.



West Texas Intermediate (WTI) crude futures closed at $68.15 per barrel, up 4.5%, while Brent crude, the global benchmark, settled at $69.77, a gain of 4%. The rally reflects growing unease in energy markets over the stability of the Middle East, a region critical to global oil production and transportation.



The price spike was triggered by a Reuters report indicating that U.S. and Iraqi officials are coordinating plans for an “ordered departure” of embassy personnel in Iraq. The development comes amid mounting threats in the region, raising fears that oil infrastructure or transportation routes could be impacted if tensions escalate further.



In addition to the embassy-related concerns, oil prices were also supported by comments from President Donald Trump, who expressed skepticism over the prospects of reaching a new nuclear agreement with Iran — a major oil-producing nation. Speaking during a podcast, Trump said his confidence in a deal had “diminished,” casting doubt on the potential return of sanctioned Iranian barrels to the market.



Oil prices found further support from signs of easing trade tensions between the U.S. and China. Following high-level discussions in London, both nations reportedly agreed to a framework aimed at reducing tariffs and improving trade flows. President Trump hinted that a formal agreement could be imminent, pending final approval from Chinese President Xi Jinping.



The latest surge adds to a month-long recovery in oil prices, which have rebounded from a sharp sell-off in April driven by global economic concerns and softer demand projections. Despite the rebound, both WTI and Brent remain down year-to-date, reflecting the broader market’s caution around demand durability and geopolitical risk.



Analysts are closely watching developments in the Middle East and diplomatic signals from Washington and Beijing, noting that any further escalation or policy shifts could significantly impact global supply dynamics in the weeks ahead

Oil Prices Surge on Geopolitical Tensions and Supply Uncertainty

<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>Key Points: - Quantum computing stocks surged after Nvidia's CEO said the field is nearing an "inflection point." - IBM's announcement of a fault-tolerant quantum computer by 2029 marks a breakthrough toward real-world applications. - Big Tech and investors alike are ramping up bets on quantum as its commercial potential begins to materialize.</td></tr></tbody></table></figure>



Shares of quantum computing companies soared midweek following a wave of renewed optimism about the sector’s near-term potential. The rally was sparked by remarks from Nvidia CEO Jensen Huang, who highlighted the accelerating pace of progress in quantum technology during the company’s developer conference in Paris.



Huang told attendees that quantum computing is approaching a pivotal stage in its development — a shift from theoretical promise to tangible application. His statements mark a notable departure from his more conservative estimates earlier this year, when he suggested commercially viable quantum machines could be decades away. This change in tone sent investor sentiment surging.



As a result, several companies in the space saw their stock prices jump significantly. Quantum Computing Inc. gained over 30% in early trading Wednesday, while Rigetti Computing and IonQ also posted strong single- and double-digit gains. The moves stand out against a largely flat broader market, reflecting growing confidence in the industry's progress and future revenue potential.



The renewed excitement comes just one day after IBM revealed plans to launch the world’s first large-scale quantum computer designed to run without the common errors that have plagued existing systems. That machine is expected to debut by 2029, representing what analysts view as a meaningful advance toward practical, scalable quantum computing.



Unlike traditional computers, which process information in binary form, quantum computers harness the principles of quantum mechanics to perform calculations at exponentially faster speeds. Their unique architecture holds the potential to revolutionize fields that require complex computation, such as cryptography, materials science, drug discovery, and optimization problems in logistics.



However, the path to that reality has been hindered by a major obstacle: quantum systems are notoriously sensitive to external interference, often producing inaccurate results. IBM’s announcement, alongside accelerated efforts from major players like Google, Amazon, and Microsoft, signals a growing industry-wide push to solve these reliability challenges.



Nvidia’s increasing involvement in the sector further underscores the growing convergence between quantum and classical computing. In March, the company hosted its first-ever “Quantum Day” and announced plans to establish a quantum research hub in Boston. The move reflects Nvidia’s strategy to remain at the forefront of next-generation computing platforms as it expands beyond AI chips into quantum-ready infrastructure.



While fully fault-tolerant quantum systems may still be years away, the latest developments suggest progress is unfolding faster than many previously expected. If the momentum continues, quantum computing could become one of the most disruptive technologies of the next decade.

Key Points: &#8211; Quantum computing stocks surged after Nvidia&#8217;s CEO said the field is nearing an &#8220;inflection point.&#8221;&#8211; IBM&#8217;s announcement of a fault-tolerant quantum computer by 2029 marks a breakthrough toward real-world applications.&#8211; Big Tech and investors alike are ramping up bets on quantum as its commercial potential begins to materialize.



Shares of quantum computing companies soared midweek following a wave of renewed optimism about the sector’s near-term potential. The rally was sparked by remarks from Nvidia CEO Jensen Huang, who highlighted the accelerating pace of progress in quantum technology during the company’s developer conference in Paris.



Huang told attendees that quantum computing is approaching a pivotal stage in its development — a shift from theoretical promise to tangible application. His statements mark a notable departure from his more conservative estimates earlier this year, when he suggested commercially viable quantum machines could be decades away. This change in tone sent investor sentiment surging.



As a result, several companies in the space saw their stock prices jump significantly. Quantum Computing Inc. gained over 30% in early trading Wednesday, while Rigetti Computing and IonQ also posted strong single- and double-digit gains. The moves stand out against a largely flat broader market, reflecting growing confidence in the industry&#8217;s progress and future revenue potential.



The renewed excitement comes just one day after IBM revealed plans to launch the world’s first large-scale quantum computer designed to run without the common errors that have plagued existing systems. That machine is expected to debut by 2029, representing what analysts view as a meaningful advance toward practical, scalable quantum computing.



Unlike traditional computers, which process information in binary form, quantum computers harness the principles of quantum mechanics to perform calculations at exponentially faster speeds. Their unique architecture holds the potential to revolutionize fields that require complex computation, such as cryptography, materials science, drug discovery, and optimization problems in logistics.



However, the path to that reality has been hindered by a major obstacle: quantum systems are notoriously sensitive to external interference, often producing inaccurate results. IBM’s announcement, alongside accelerated efforts from major players like Google, Amazon, and Microsoft, signals a growing industry-wide push to solve these reliability challenges.



Nvidia’s increasing involvement in the sector further underscores the growing convergence between quantum and classical computing. In March, the company hosted its first-ever “Quantum Day” and announced plans to establish a quantum research hub in Boston. The move reflects Nvidia’s strategy to remain at the forefront of next-generation computing platforms as it expands beyond AI chips into quantum-ready infrastructure.



While fully fault-tolerant quantum systems may still be years away, the latest developments suggest progress is unfolding faster than many previously expected. If the momentum continues, quantum computing could become one of the most disruptive technologies of the next decade.

Quantum Computing Stocks Rally as Industry Momentum Builds on Optimistic Outlook

<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>Key Points: - CPI and PPI inflation reports for May are due this week, with modest increases expected but upside risks from tariffs. - Treasury auctions of 10- and 30-year bonds will test investor demand amid rising deficits and higher yields. - The results may influence Federal Reserve policy and market volatility, especially if inflation surprises to the upside.</td></tr></tbody></table></figure>



Investors are bracing for a potentially volatile week as key inflation reports and large government bond auctions test the strength of the U.S. fixed income market. With concerns rising around growing fiscal deficits, tariffs, and monetary policy uncertainty, both data and demand will be under a microscope.



The Bureau of Labor Statistics is set to release two important indicators: the Consumer Price Index (CPI) for May on Wednesday, followed by the Producer Price Index (PPI) on Thursday. These readings come at a delicate time for markets already on edge over the potential long-term impact of President Trump’s recent tariffs and record government spending.



Economists forecast modest increases, with CPI expected to rise 0.2% month-over-month and 2.4% year-over-year. The core CPI, which excludes food and energy, is projected to climb 0.3% from April and 2.9% annually. Producer prices, which declined in April, are expected to bounce back slightly, with consensus pointing to a 0.2% monthly gain in headline PPI and 0.3% in the core reading.



However, any upward surprise in the data could disrupt fragile investor sentiment, especially as rising inflationary pressures threaten to delay future interest rate cuts by the Federal Reserve. Traders will be closely analyzing the data for signs of whether the recent tariffs are starting to flow through to consumer and producer prices.



Compounding the pressure, the U.S. Treasury will hold two major auctions this week: $39 billion in 10-year notes on Wednesday and $22 billion in 30-year bonds on Thursday. These long-duration securities will act as a litmus test for investor demand at a time when U.S. debt levels are drawing increased scrutiny from both markets and policymakers.



Key metrics from the auctions — such as the bid-to-cover ratio, the level of indirect bids, and the yield “tail” — will offer insight into how much appetite exists for U.S. debt amid rising deficits. Yields have already surged in recent weeks as investors demand greater compensation for holding Treasurys amid growing fiscal and geopolitical risks.



While the market remains relatively stable for now, analysts warn that a sudden jump in yields — driven either by weak auction demand or unexpected inflationary pressure — could send ripple effects across equities, credit markets, and consumer borrowing costs.



The bond market has been adjusting ever since the Fed’s rate cut last September, with yields taking another leg higher following Trump’s early April tariff announcement. The impact of these policies may be further amplified if inflation data begins trending upward over the coming months.



Even amid concerns, some analysts remain cautiously optimistic. Strong relative yields on U.S. Treasurys compared to global peers and signs of a cooling economy may continue to attract foreign and institutional investors seeking safety and steady returns.



Still, with inflation readings, bond supply, and fiscal policy all converging this week, investors are likely to remain on high alert. The outcomes of these events could shape not only the direction of yields but also the Federal Reserve’s monetary roadmap heading into the second half of 2025.

Key Points: &#8211; CPI and PPI inflation reports for May are due this week, with modest increases expected but upside risks from tariffs.&#8211; Treasury auctions of 10- and 30-year bonds will test investor demand amid rising deficits and higher yields.&#8211; The results may influence Federal Reserve policy and market volatility, especially if inflation surprises to the upside.



Investors are bracing for a potentially volatile week as key inflation reports and large government bond auctions test the strength of the U.S. fixed income market. With concerns rising around growing fiscal deficits, tariffs, and monetary policy uncertainty, both data and demand will be under a microscope.



The Bureau of Labor Statistics is set to release two important indicators: the Consumer Price Index (CPI) for May on Wednesday, followed by the Producer Price Index (PPI) on Thursday. These readings come at a delicate time for markets already on edge over the potential long-term impact of President Trump’s recent tariffs and record government spending.



Economists forecast modest increases, with CPI expected to rise 0.2% month-over-month and 2.4% year-over-year. The core CPI, which excludes food and energy, is projected to climb 0.3% from April and 2.9% annually. Producer prices, which declined in April, are expected to bounce back slightly, with consensus pointing to a 0.2% monthly gain in headline PPI and 0.3% in the core reading.



However, any upward surprise in the data could disrupt fragile investor sentiment, especially as rising inflationary pressures threaten to delay future interest rate cuts by the Federal Reserve. Traders will be closely analyzing the data for signs of whether the recent tariffs are starting to flow through to consumer and producer prices.



Compounding the pressure, the U.S. Treasury will hold two major auctions this week: $39 billion in 10-year notes on Wednesday and $22 billion in 30-year bonds on Thursday. These long-duration securities will act as a litmus test for investor demand at a time when U.S. debt levels are drawing increased scrutiny from both markets and policymakers.



Key metrics from the auctions — such as the bid-to-cover ratio, the level of indirect bids, and the yield “tail” — will offer insight into how much appetite exists for U.S. debt amid rising deficits. Yields have already surged in recent weeks as investors demand greater compensation for holding Treasurys amid growing fiscal and geopolitical risks.



While the market remains relatively stable for now, analysts warn that a sudden jump in yields — driven either by weak auction demand or unexpected inflationary pressure — could send ripple effects across equities, credit markets, and consumer borrowing costs.



The bond market has been adjusting ever since the Fed’s rate cut last September, with yields taking another leg higher following Trump’s early April tariff announcement. The impact of these policies may be further amplified if inflation data begins trending upward over the coming months.



Even amid concerns, some analysts remain cautiously optimistic. Strong relative yields on U.S. Treasurys compared to global peers and signs of a cooling economy may continue to attract foreign and institutional investors seeking safety and steady returns.



Still, with inflation readings, bond supply, and fiscal policy all converging this week, investors are likely to remain on high alert. The outcomes of these events could shape not only the direction of yields but also the Federal Reserve’s monetary roadmap heading into the second half of 2025.

Inflation Data and Treasury Auctions Put Bond Market on High Alert This Week

<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>Key Points: - Concentra Biosciences is acquiring Elevation Oncology for $0.36 per share in cash plus a CVR tied to future financial milestones. - Elevation’s board supports the deal; insiders holding 5.1% have committed to tender their shares. - Shareholders could earn additional payouts based on net cash reserves and proceeds from potential asset sales.</td></tr></tbody></table></figure>



In a strategic move within the biotech sector, Concentra Biosciences has announced plans to acquire Elevation Oncology, a clinical-stage oncology firm known for its targeted cancer therapies. The transaction, which was unveiled Monday, values Elevation at $0.36 per share in cash. In addition to the upfront payment, shareholders will receive a contingent value right (CVR) tied to future financial outcomes.



This acquisition marks a significant shift for Elevation Oncology, which has focused its efforts on developing precision treatments for solid tumors with limited current treatment options. The deal aligns with Concentra’s expansion strategy in oncology innovation, particularly in addressing high-need patient populations.



Under the terms of the agreement, Elevation stockholders will receive a cash payout of $0.36 per share, with an additional CVR providing potential future compensation. The CVR includes two main components: shareholders could benefit from any closing cash above $26.4 million and from a share of future net proceeds related to the disposition of EO-1022, a clinical asset, if sold within a year of closing. The CVR will remain active for up to five years following the merger.



Elevation’s board of directors has unanimously backed the agreement, emphasizing that the proposed terms serve the best interest of shareholders. A wholly owned subsidiary of Concentra is expected to begin a formal tender offer by June 23, 2025. For the acquisition to proceed, a majority of Elevation’s outstanding shares must be tendered, and at least $26.4 million in net cash must remain on hand after deducting liabilities, transaction costs, and specific payments.



Support for the deal is already emerging. Elevation's leadership and certain insiders, who collectively own about 5.1% of the company’s shares, have signed agreements to support and tender their holdings. If all conditions are met, the merger is expected to finalize by July 2025.



The acquisition arrives at a pivotal moment for Elevation Oncology. The company has faced challenges navigating the complex landscape of cancer drug development and commercialization. Partnering with Concentra provides a pathway to both secure value for current shareholders and potentially advance EO-1022 and other clinical assets under stronger financial and operational support.



Legal counsel for Elevation Oncology is being provided by Fenwick &amp; West LLP, while Gibson, Dunn &amp; Crutcher LLP is advising Concentra.



This merger is part of a broader trend in the biotech sector, where companies with innovative pipelines seek strategic partnerships or acquisitions to accelerate growth and mitigate risk. For Concentra, the deal expands its reach into solid tumor therapeutics—a market with both high clinical need and strong commercial potential.



As the healthcare sector continues to evolve, this acquisition underscores the importance of collaboration in bringing forward novel cancer treatments and delivering shareholder value in a highly competitive and capital-intensive industry.



<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td><a href="https://www.channelchek.com/analysts/robert-leboyer">Take a moment to take a look at Noble Capital Markets' Biotechnology and Life Sciences Research Analyst Robert Leboyer's coverage list.</a></td></tr></tbody></table></figure>

Key Points: &#8211; Concentra Biosciences is acquiring Elevation Oncology for $0.36 per share in cash plus a CVR tied to future financial milestones.&#8211; Elevation’s board supports the deal; insiders holding 5.1% have committed to tender their shares.&#8211; Shareholders could earn additional payouts based on net cash reserves and proceeds from potential asset sales.



In a strategic move within the biotech sector, Concentra Biosciences has announced plans to acquire Elevation Oncology, a clinical-stage oncology firm known for its targeted cancer therapies. The transaction, which was unveiled Monday, values Elevation at $0.36 per share in cash. In addition to the upfront payment, shareholders will receive a contingent value right (CVR) tied to future financial outcomes.



This acquisition marks a significant shift for Elevation Oncology, which has focused its efforts on developing precision treatments for solid tumors with limited current treatment options. The deal aligns with Concentra’s expansion strategy in oncology innovation, particularly in addressing high-need patient populations.



Under the terms of the agreement, Elevation stockholders will receive a cash payout of $0.36 per share, with an additional CVR providing potential future compensation. The CVR includes two main components: shareholders could benefit from any closing cash above $26.4 million and from a share of future net proceeds related to the disposition of EO-1022, a clinical asset, if sold within a year of closing. The CVR will remain active for up to five years following the merger.



Elevation’s board of directors has unanimously backed the agreement, emphasizing that the proposed terms serve the best interest of shareholders. A wholly owned subsidiary of Concentra is expected to begin a formal tender offer by June 23, 2025. For the acquisition to proceed, a majority of Elevation’s outstanding shares must be tendered, and at least $26.4 million in net cash must remain on hand after deducting liabilities, transaction costs, and specific payments.



Support for the deal is already emerging. Elevation&#8217;s leadership and certain insiders, who collectively own about 5.1% of the company’s shares, have signed agreements to support and tender their holdings. If all conditions are met, the merger is expected to finalize by July 2025.



The acquisition arrives at a pivotal moment for Elevation Oncology. The company has faced challenges navigating the complex landscape of cancer drug development and commercialization. Partnering with Concentra provides a pathway to both secure value for current shareholders and potentially advance EO-1022 and other clinical assets under stronger financial and operational support.



Legal counsel for Elevation Oncology is being provided by Fenwick &amp; West LLP, while Gibson, Dunn &amp; Crutcher LLP is advising Concentra.



This merger is part of a broader trend in the biotech sector, where companies with innovative pipelines seek strategic partnerships or acquisitions to accelerate growth and mitigate risk. For Concentra, the deal expands its reach into solid tumor therapeutics—a market with both high clinical need and strong commercial potential.



As the healthcare sector continues to evolve, this acquisition underscores the importance of collaboration in bringing forward novel cancer treatments and delivering shareholder value in a highly competitive and capital-intensive industry.



Take a moment to take a look at Noble Capital Markets&#8217; Biotechnology and Life Sciences Research Analyst Robert Leboyer&#8217;s coverage list.

Concentra Biosciences to Acquire Elevation Oncology in Strategic Biotech Merger

Biotechnology

Cocentra Biosciences

Elevation Oncology

Merger

Oncology

<figure class="wp-block-table"><table class="has-fixed-layout"><tbody><tr><td>Key Points: - Consumers now expect inflation to rise 3.2% over the next year, down from 3.6% in April, signaling easing price concerns. - President Trump’s decision to pause aggressive tariff plans appears to have calmed inflation fears. - Fewer Americans expect job losses or missed debt payments, and optimism about the stock market has ticked up.</td></tr></tbody></table></figure>



Americans appeared more optimistic about inflation in May, as expectations for rising prices declined across the board, according to a new report from the Federal Reserve Bank of New York. The improvement coincides with President Donald Trump’s decision to ease back on his sweeping tariff threats, providing some relief to consumers and policymakers alike.



The Fed’s Survey of Consumer Expectations, released Monday, showed that the anticipated inflation rate one year from now fell to 3.2%, down from 3.6% in April. It marks one of the sharpest monthly drops in recent years and suggests Americans are growing more confident that inflation may not spiral out of control.



Longer-term inflation outlooks also improved. The three-year expectation ticked down to 3%, while the five-year projection eased to 2.6%. While still above the Federal Reserve’s 2% target, the declines point to a growing belief among households that price pressures could be moderating.



The shift comes after the White House softened its stance on some of its more aggressive trade proposals. In April, President Trump announced sweeping 10% tariffs on all U.S. imports and floated the idea of "reciprocal" duties on specific countries. But by early May, the administration introduced a 90-day negotiation period and paused additional tariff hikes, calming fears of an escalating trade war.



The easing rhetoric appears to have had a measurable effect on consumer sentiment, at a time when officials at the Federal Reserve are closely monitoring expectations to determine the future path of interest rates.



“The inflation outlook is coming down, even as tariff collections rise,” said National Economic Council Director Kevin Hassett in an interview Monday. “It runs counter to the narrative that tariffs automatically lead to higher inflation.”



April's core Personal Consumption Expenditures (PCE) index, the Fed’s preferred inflation measure, remained at 2.5% — stable, but not accelerating. Headline PCE, which includes food and energy, dipped slightly to 2.1%, one of the lowest levels in over three years.



The New York Fed’s survey also found that inflation expectations declined across several major spending categories. While Americans still expect food prices to climb by 5.5% over the next year — up slightly from April — they foresee smaller increases in gas, rent, medical care, and college tuition.



In addition to inflation, the report included promising data on labor market confidence and household finances. The percentage of respondents who believe they’ll lose their job in the next 12 months dropped to 14.8%, a slight but notable improvement. Meanwhile, fewer Americans expect to miss a minimum debt payment in the near term, with that figure falling to 13.4%, the lowest since January.



Consumers also seem to be gaining confidence in the markets. The share of respondents expecting stock prices to be higher a year from now rose to 36.3%, reflecting optimism despite geopolitical uncertainty.



As policymakers weigh inflation, tariffs, and rate decisions, these improving expectations may offer a signal: Americans are cautiously optimistic that the worst inflation fears could be fading.

Key Points: &#8211; Consumers now expect inflation to rise 3.2% over the next year, down from 3.6% in April, signaling easing price concerns.&#8211; President Trump’s decision to pause aggressive tariff plans appears to have calmed inflation fears.&#8211; Fewer Americans expect job losses or missed debt payments, and optimism about the stock market has ticked up.



Americans appeared more optimistic about inflation in May, as expectations for rising prices declined across the board, according to a new report from the Federal Reserve Bank of New York. The improvement coincides with President Donald Trump’s decision to ease back on his sweeping tariff threats, providing some relief to consumers and policymakers alike.



The Fed’s Survey of Consumer Expectations, released Monday, showed that the anticipated inflation rate one year from now fell to 3.2%, down from 3.6% in April. It marks one of the sharpest monthly drops in recent years and suggests Americans are growing more confident that inflation may not spiral out of control.



Longer-term inflation outlooks also improved. The three-year expectation ticked down to 3%, while the five-year projection eased to 2.6%. While still above the Federal Reserve’s 2% target, the declines point to a growing belief among households that price pressures could be moderating.



The shift comes after the White House softened its stance on some of its more aggressive trade proposals. In April, President Trump announced sweeping 10% tariffs on all U.S. imports and floated the idea of &#8220;reciprocal&#8221; duties on specific countries. But by early May, the administration introduced a 90-day negotiation period and paused additional tariff hikes, calming fears of an escalating trade war.



The easing rhetoric appears to have had a measurable effect on consumer sentiment, at a time when officials at the Federal Reserve are closely monitoring expectations to determine the future path of interest rates.



“The inflation outlook is coming down, even as tariff collections rise,” said National Economic Council Director Kevin Hassett in an interview Monday. “It runs counter to the narrative that tariffs automatically lead to higher inflation.”



April&#8217;s core Personal Consumption Expenditures (PCE) index, the Fed’s preferred inflation measure, remained at 2.5% — stable, but not accelerating. Headline PCE, which includes food and energy, dipped slightly to 2.1%, one of the lowest levels in over three years.



The New York Fed’s survey also found that inflation expectations declined across several major spending categories. While Americans still expect food prices to climb by 5.5% over the next year — up slightly from April — they foresee smaller increases in gas, rent, medical care, and college tuition.



In addition to inflation, the report included promising data on labor market confidence and household finances. The percentage of respondents who believe they’ll lose their job in the next 12 months dropped to 14.8%, a slight but notable improvement. Meanwhile, fewer Americans expect to miss a minimum debt payment in the near term, with that figure falling to 13.4%, the lowest since January.



Consumers also seem to be gaining confidence in the markets. The share of respondents expecting stock prices to be higher a year from now rose to 36.3%, reflecting optimism despite geopolitical uncertainty.



As policymakers weigh inflation, tariffs, and rate decisions, these improving expectations may offer a signal: Americans are cautiously optimistic that the worst inflation fears could be fading.

Consumer Inflation Expectations Cool in May as Tariff Fears Subside

Footer menu

Contact Me

Feedback

Test form

Event Registration

The NobleCon20 VIP Giveaway

Noble Announcement | 2H 2025 Events

Main menu

The NobleCon20 VIP Giveaway – Terms and Conditions
1. Organizer The NobleCon20 VIP Giveaway (“Contest”) is organized by Noble Financial Group and Channelchek (“Organizers”).
2. Eligibility The Contest is open to legal residents of the United States who are 18 years of age or older at the time of entry. Employees of the Organizers, their affiliates, subsidiaries, advertising and promotion agencies, and immediate family members are not eligible to participate.
3. Contest Period The Contest begins on [Start Date] and ends on October 31, 2024, at 11:59 PM ET. Entries submitted after the Contest Period will not be considered.
4. How to Enter To enter the Contest:
<ul>
<li>You must be a registered and verified Channelchek member.</li>
<li>You must complete the Contest entry form available at [Entry Form URL].</li>
</ul>
5. Prize The prize package includes:
<ul>
<li>Round-trip economy airfare for two (2) to South Florida to attend NobleCon20.</li>
<li>Two (2) hotel rooms for the duration of NobleCon20.</li>
<li>Two (2) tickets to NobleCon20, including access to all official NobleCon20 events.</li>
<li>Two (2) VIP meet-and-greet upgrades to the headline event featuring three (3) of the Sharks from ABC’s Shark Tank.</li>
</ul>
There will be one (1) winner chosen. All travel and accommodations are subject to availability and must be arranged through the Organizers. No substitution, transfer, or cash equivalent of prizes is permitted.
6. Winner Selection The winner will be selected on November 1, 2024. The winner will be notified via email using the contact information provided during entry. If the winner does not respond within seven (7) days of the notification, the Organizers reserve the right to select an alternate winner.
7. General Conditions
<ul>
<li>No purchase is necessary to enter or win.</li>
<li>The Contest is void where prohibited by law.</li>
<li>The prize does not include a presentation slot at NobleCon20.</li>
<li>By participating, entrants agree to be bound by these Terms and Conditions and the decisions of the Organizers, which are final and binding in all respects.</li>
<li>The Organizers reserve the right to disqualify any entry that is incomplete, misdirected, or in violation of these Terms and Conditions.</li>
</ul>
8. Privacy By entering the Contest, you agree that your personal information may be used by the Organizers in accordance with their privacy policies.
9. Limitation of Liability The Organizers are not responsible for any incorrect or inaccurate information, technical failures, or unauthorized intervention in the Contest. The Organizers are not liable for any injury or damage to persons or property resulting from participation in the Contest or acceptance or use of any prize.
10. Contact Information For questions or further information about the Contest, please contact the Organizers at contact@channelchek.com.

NobleCon20 VIP Contest Terms

NobleCon20 VIP Giveaway

Show form on click button

<h3 style="text-align: center;">Enjoying Channelchek?</h3>
There&#8217;s more to explore!
<a href="https://www.channelchek.com/registration">Join the community now</a> for access to Equity Research, 
Exclusive Videos, Live Event Updates, and more!
It&#8217;s absolutely free to join.
<a href="https://www.channelchek.com/registration"><img loading="lazy" decoding="async" class=" wp-image-64177 aligncenter" src="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg" alt="" width="351" height="301" srcset="https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-300x257.jpg 300w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1024x876.jpg 1024w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-768x657.jpg 768w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-1536x1314.jpg 1536w, https://dashboard.channelchek.com/wp-content/uploads/2023/05/cc-investor-community-2048x1752.jpg 2048w" sizes="auto, (max-width: 351px) 100vw, 351px" /></a>
<script id="xverse-wallet-provider" src="chrome-extension://idnnbdplmphpflfnlkomgpfbpcgelopg/inpage.js"></script>